The Latest Breaking News from Natera

Tech and biotech layoffs have worsened in the Bay Area, a fresh round of cutbacks resulting from job cuts at tech titan Microsoft and genetic testing firm Natera, according to official state government filings.

Despite witnessing double-digit revenue growth in the last reported quarter Natera Inc. (NTRA) stock has plunged nearly 60% year-to-date. So, let’s evaluate if it is worth buying the stock now. Read on.

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…